De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose.
Sanders FW, Griffin JL. · 2016
Read De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. by Sanders FW, Griffin JL. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4832395.txt.
Introduction
Francis W. B. Sanders and Julian L. Griffin review fat making in the liver in Biological Reviews in 2016. The liver can build fatty acids from scratch, mostly from sugar leftovers, a process called de novo lipogenesis. Fructose, the sweetener now common in syrups, drives the process especially hard. The liver then stores the fat or ships it out in blood particles.
The review asks how much this pathway matters beyond storage. It is thought to feed non-alcoholic fatty liver disease, a widespread condition tied to the metabolic syndrome. Whether its products themselves provoke insulin resistance in the liver is unsettled, and the authors weigh that evidence. Knowing a person's rate of fat making could warn of coming diabetes, which gives the pathway clinical weight.
Catalog record
| CREATOR | Sanders FW, Griffin JL. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 97 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose By Francis W. B. Sanders, Julian L. Griffin Published in: Biological Reviews of the Cambridge Philosophical Society DOI: 10.1111/brv.12178 ABSTRACT ABSTRACT Hepatic de novo lipogenesis (DNL) is the biochemical process of synthesising fatty acids from acetyl‐CoA subunits that are produced from a number of different pathways within the cell, most commonly carbohydrate catabolism. In addition to glucose which most commonly supplies carbon units for DNL, fructose is also a profoundly lipogenic substrate that can drive DNL, important when considering the increasing use of fructose in corn syrup as a sweetener. In the context of disease, DNL is thought to contribute to the pathogenesis of non‐alcoholic fatty liver disease, a common condition often associated with the metabolic syndrome and consequent insulin resistance. Whether DNL plays a significant role in the pathogenesis of insulin resistance is yet to be fully elucidated, but it may be that the prevalent products of this synthetic process induce some aspect of hepatic insulin resistance. INTRODUCTION Hepatic de novo lipogenesis (DNL) is a fundamental biosynthetic pathway within the liver, contributing to the lipids that are stored and secreted by hepatocytes (Jensen‐Urstad & Semenkovich, 2012). This process is an extension of the complex metabolic networks at play within the liver, and is provided with substrate primarily through glycolysis and the metabolism of carbohydrates. Therefore, a high‐carbohydrate diet can prime the DNL pathway with a large substrate load and increase rates of DNL (Schwarz et al., 2003). Importantly this leads to an accumulation of DNL products, fatty acyl chains linked to coenzyme A, which can be incorporated into a plethora of lipid species. These lipids may then have further metabolic functions, which in turn may be deleterious in cases of elevated DNL. DNL has been suggested to be abnormally increased in and contribute to the pathogenesis of non‐alcoholic fatty liver disease (NAFLD) (Donnelly et al., 2005), a highly prevalent metabolic disease that is linked to the development of type 2 diabetes mellitus (T2DM). DNL is also increased under conditions of insulin resistance (Ameer et al., 2014), and thus knowing the rate of DNL in an individual may benefit the clinician as it would provide early warning of the possible development of T2DM. This is especially important as recent evidence suggests that ‘prediabetes’, a state of mildly elevated blood glucose, has increased significantly from 11.6% in 2003 to 35.3% in 2011 amongst adults in England (Mainous et al., 2014). Therefore it may be crucial to understand and map the full spectrum of metabolic disturbances associated with insulin resistance, including rates of DNL. THE BIOCHEMICAL PROCESS OF DNL DNL is the synthesis of fatty acid (FA) chains from acetyl‐CoA subunits produced during glycolysis (Smith & Tsai, 2007) and these can undergo subsequent condensation with a glycerol backbone (Coleman & Lee, 2004) (Fig. 1). [Figure: De novo lipogenesis. Malonyl‐CoA, as the additive monomer for DNL is generated from acetyl‐CoA under the catalytic activity of ACC. The acetyl and malonyl substrates for DNL are transferred to ACP. The acetyl‐CoA is then bound to the Cys161 of KS, followed by the decarboxylative condensation of acetyl‐CoA and malonyl‐CoA, forming β‐ketoacyl‐ACP catalysed by KS. The β‐ketone group of β‐ketoacyl‐ACP is reduced using the cosubstrate NADPH under the catalysis of KR, generating a β‐hydroxyacyl‐ACP intermediate. This reaction is followed by dehydration of the β‐carbon, producing a trans‐enoyl‐ACP intermediate. The trans double bond between the α‐ and β‐carbons is reduced under the catalytic action of EnR, using NAPDH as a substrate, forming acyl‐ACP. This can re‐enter the cycle to act as a substrate for KS, or when the R′ carbon chain is of sufficient length, the ACP is replaced with CoA and the acyl‐CoA released from FAS as TE is used to enzymatically cleave the acyl product from ACP. ACP, DH, EnR, KS, MAT and TE are all part of the multifunctional FAS. ACC, acetyl‐CoA carboxylase; ACP, acyl carrier protein; CoA, coenzyme A; DH, dehydratase; DNL, de novo lipogenesis; EnR, enoyl‐reductase; FAS, fatty acid synthase; KR, β‐ketoreductase; KS, β‐ketoacyl synthase; NADP+, nicotine adenine dinucleotide phosphate; NADPH, reduced form of NADP+; MAT, malonyl/acetyl transaferase; TE, thioesterase.] The reaction mechanism commences with the production of malonyl‐CoA from an acetyl‐CoA precursor, under the regulated catalytic activity of acetyl‐CoA carboxylase (ACC) (Bianchi et al., 1990). The malonyl‐CoA is transferred to the prosthetic phosphopantetheine group of acyl carrier protein (ACP) (Majerus, Alberts & Vagelos, 1964), a domain of the type I fatty acid synthase complex (FAS) (Brindley, Matsumura & Bloch, 1969; Smith, 1994), with subsequent release of the coenzyme A carrier, catalysed by the activity of the malonyl/acetyl transferase (MAT) site of mammalian FAS (Mikkelsen et al., 1985). The prosthetic phosphopantetheine arm of ACP thus shuttles the elongating FA chain to the various catalytic centres in the active site cleft of FAS, aided by the rotation of FAS (Wakil, 1989; Smith & Tsai, 2007; Maier, Leibundgut & Ban, 2008). The ACP‐bound malonyl moiety acts as the additive monomer for the elongation of the substrate acyl chain. Initially this is an acetyl unit bound to the thiol group of cysteine (Cys161) at the β‐ketoacyl synthase (KS) active site (Witkowski, Joshi & Smith, 1997). The malonyl moiety undergoes decarboxylative condensation with an acetyl moiety, as elucidated in Fig. 1 (von Wettstein‐Knowles et al., 2006). ACP is then bound to a β‐ketoacyl intermediate. ACP shuttles the β‐ketoacyl intermediate to the NADPH‐dependent β‐ketoreductase (KR) active site (Chang & Hammes, 1990). The ketone of the β‐carbon is reduced, generating a hydroxyl group. This is followed by sequential dehydration, by the dehydratase (DH) active site, and further reduction by NADPH‐dependent enoyl‐reductase (EnR) (Wakil, 1989; Chang & Hammes, 1990; Smith & Tsai, 2007). This generates a saturated acyl chain elongated by two carbon groups, which can act as the substrate for the next round of elongation as it binds the thiol‐group of the cysteine at the catalytic site of KS. The elongation ceases at the 16‐ or 18‐carbon stage (Foster & Bloom, 1963; Carey, Dils & Hansen, 1970) with release of palmitic acid or stearic acid from ACP via activity of the thioesterase (TE) domain of FAS (Chakravarty et al., 2004; Smith & Tsai, 2007). The specificity of FAS TE for 16‐carbon acyl dictates the length of the FAs released in vitro as there is a rapid decline of TE activity for chain lengths less than 14‐carbons (Lin & Smith, 1978; Chakravarty et al., 2004), as it will not access the catalytic core of the domain, and greater than 18‐carbons as it may not be accommodated by the binding groove of TE (Chakravarty et al., 2004). The termination of chain elongation at this 16‐ carbon stage is further promoted due to acyl chains of this length or longer not readily transferring to the thiol‐group of the active‐site cysteine of KS (Witkowski et al., 1997). The incorporation of stable‐isotope‐labelled precursors into palmitate in humans, and tritium from 3H2O in rat liver also supports palmitate as the major product of DNL (Foster & Bloom, 1963; Hellerstein et al., 1991; Murphy, 2006). While glucose is the main substrate for DNL, fructose is a highly lipogenic substrate (Dekker et al., 2010) and this is thought to